CA3011766C - Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione - Google Patents
Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione Download PDFInfo
- Publication number
- CA3011766C CA3011766C CA3011766A CA3011766A CA3011766C CA 3011766 C CA3011766 C CA 3011766C CA 3011766 A CA3011766 A CA 3011766A CA 3011766 A CA3011766 A CA 3011766A CA 3011766 C CA3011766 C CA 3011766C
- Authority
- CA
- Canada
- Prior art keywords
- acid
- crystalline form
- sodium
- luminol
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16000380 | 2016-02-16 | ||
| EP16000380.2 | 2016-02-16 | ||
| PCT/EP2017/000209 WO2017140422A1 (en) | 2016-02-16 | 2017-02-15 | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3011766A1 CA3011766A1 (en) | 2017-08-24 |
| CA3011766C true CA3011766C (en) | 2023-08-01 |
Family
ID=55361317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3011766A Active CA3011766C (en) | 2016-02-16 | 2017-02-15 | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11203575B2 (enExample) |
| EP (1) | EP3416952B1 (enExample) |
| JP (1) | JP6949856B2 (enExample) |
| KR (1) | KR102535959B1 (enExample) |
| CN (1) | CN109071461B (enExample) |
| CA (1) | CA3011766C (enExample) |
| ES (1) | ES2796476T3 (enExample) |
| WO (1) | WO2017140422A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3511325A1 (en) * | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
| EP3870175B1 (en) * | 2018-10-26 | 2024-08-28 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis |
| EP3858328A1 (en) * | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| PL4125802T3 (pl) * | 2020-03-25 | 2026-03-23 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc |
| AU2021288757B2 (en) * | 2020-06-10 | 2026-01-08 | Metriopharm Ag | Compound for the treatment of coronaviral infections |
| KR20230116786A (ko) | 2020-12-01 | 2023-08-04 | 리버스피에이에이치 엘엘씨 | 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물 |
| US20240075029A1 (en) * | 2020-12-02 | 2024-03-07 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
| EP4460309B1 (en) * | 2022-01-07 | 2026-08-19 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743541A (en) * | 1985-07-17 | 1988-05-10 | Mast Immunosystems, Inc. | Luminescent substrate preparation and its use in specific binding assays |
| FR2839155B1 (fr) * | 2002-04-25 | 2005-02-04 | Roc Imp | Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang |
| BRPI0307864B1 (pt) * | 2003-11-25 | 2016-01-12 | Univ Rio De Janeiro | processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos |
| CN100390152C (zh) * | 2006-03-23 | 2008-05-28 | 潘健 | 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法 |
| PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| PT2542535E (pt) * | 2010-03-01 | 2014-08-25 | Metriopharm Ag | Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas |
| WO2011123776A2 (en) * | 2010-04-01 | 2011-10-06 | Guthery B Eugene | Method for detecting occult blood |
| US20110246075A1 (en) * | 2010-04-01 | 2011-10-06 | Banik Niranjan C | Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure |
-
2017
- 2017-02-15 WO PCT/EP2017/000209 patent/WO2017140422A1/en not_active Ceased
- 2017-02-15 US US15/999,050 patent/US11203575B2/en active Active
- 2017-02-15 EP EP17711562.3A patent/EP3416952B1/en active Active
- 2017-02-15 CN CN201780023173.7A patent/CN109071461B/zh active Active
- 2017-02-15 ES ES17711562T patent/ES2796476T3/es active Active
- 2017-02-15 KR KR1020187026714A patent/KR102535959B1/ko active Active
- 2017-02-15 CA CA3011766A patent/CA3011766C/en active Active
- 2017-02-15 JP JP2018542754A patent/JP6949856B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3416952B1 (en) | 2020-04-08 |
| EP3416952A1 (en) | 2018-12-26 |
| US20200369623A1 (en) | 2020-11-26 |
| JP6949856B2 (ja) | 2021-10-13 |
| JP2019504865A (ja) | 2019-02-21 |
| CN109071461A (zh) | 2018-12-21 |
| CN109071461B (zh) | 2022-06-21 |
| US11203575B2 (en) | 2021-12-21 |
| CA3011766A1 (en) | 2017-08-24 |
| KR20180107278A (ko) | 2018-10-01 |
| ES2796476T3 (es) | 2020-11-27 |
| KR102535959B1 (ko) | 2023-05-23 |
| WO2017140422A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3011767C (en) | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione | |
| EP3416952B1 (en) | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione | |
| EP4178579B1 (en) | 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent | |
| WO2017202496A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae | |
| JP7807378B2 (ja) | 稀な慢性炎症性肺疾患の治療における５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオンの使用 | |
| JP2024516340A (ja) | Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール | |
| HK40001510B (en) | Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione | |
| HK40001510A (en) | Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione | |
| HK40001511A (en) | Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210420 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250129 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250129 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |